SZSiyuan Zhao

Siyuan Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Siyuan Zhao has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Kourong Shi

    Department of Pharmacy, Seventh People's Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200137, China

    4 shared publications
  • Wei Fan

    Department of Pharmacy, Seventh People's Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200137, China

    4 shared publications
  • Cuiping Li

    Department of Pharmacy & Innovative Chinese Medicine Research Institute, The Seventh People's Affiliated Hospital of Shanghai University of Traditional Chinese Medicine

    3 shared publications
  • Juan Liu

    Department of Pharmacy & Innovative Chinese Medicine Research Institute, The Seventh People's Affiliated Hospital of Shanghai University of Traditional Chinese Medicine

    3 shared publications
  • Xin Wu

    Fujian University of Traditional Chinese Medicine, Fuzhou, China

    3 shared publications
  • Qiaoli Zhai

    Department of Pharmacy & Innovative Chinese Medicine Research Institute, The Seventh People's Affiliated Hospital of Shanghai University of Traditional Chinese Medicine

    2 shared publications

Latest Publications

  • Open Access

    iRGD-modified peptide–drug conjugate improves brain delivery and antitumor efficacy in glioblastoma

    by Danyang Yun, Lizhen Mu, Juan Liu, Cuiping Li, Siyuan Zhao, Qiaoli Zhai, Huan Sun, Xin Wu, Kourong Shi, Wei Fan

  • Open Access

    Anthraquinone-Loaded Liposomes for TAM Reprogramming in Triple-Negative Breast Cancer: Mechanistic Rationale, Delivery Logic, and Translational Challenges

    by Limin Zhai, Juan Liu, Lizhen Mu, Cuiping Li, Siyuan Zhao, Ting Li, Qiuzhen Zhu, Xiaoli Hou, Kourong Shi, Wei Fan

    Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by limited actionable targets, early recurrence, metastatic propensity, and variable responses to immune checkpoint blockade. Therapeutic resistance is closely associated with myeloid immunosuppression, in which tumor-associated macrophages (TAMs) promote T-cell exclusion, stromal remodeling, angiogenesis, metabolic dysfunction, and resistance to cytotoxic and immune-based therapies. Anthraquinone compounds, including emodin, aloe-emodin, rhein, and chrysophanol, may support TAM reprogramming by regulating tumor-cell stress responses, endoplasmic reticulum stress, immunogenic cell death-associated signaling, redox balance, immunometabolism, and STAT3/NF-κB-related inflammatory pathways. However, poor aqueous solubility, heterogeneous biodistribution, unstable systemic exposure, and potential off-target toxicity limit their translational development. Liposomal delivery offers a formulation strategy to improve solubilization, biodistribution, TAM-associated uptake/engagement, intracellular release, and therapeutic exposure windows. This review discusses anthraquinone-loaded liposomes for TAM reprogramming in TNBC by integrating mechanistic rationale, evidence boundaries, delivery logic, formulation determinants, and translational challenges, with particular attention to stress chaperone proteins, lipid composition, vesicle lamellarity, membrane phase state, responsive release, clinically relevant liposomal formulations, and clinical developability. Overall, anthraquinone-loaded liposomes are better positioned as immune microenvironment recalibration platforms or synergistic modulators in combination therapy rather than as standalone cytotoxic agents for TNBC.


  • 5-Fluorouracil-methotrexate conjugate enhances the efficacy of 5-fluorouracil in colorectal cancer therapy

    by Siyuan Zhao, Tiansi Wang, Kourong Shi, Ting Li, Qiuzhen Zhu, Yuan Li, Beiwei Xin, Xin Wu, Wei Fan

    To extend the short half-life of fluorouracil (Fu), enhance its tumor targeting, improve efficacy, and reduce side effects, providing a new approach for colorectal cancer treatment. Fluorouracil was hydroxylated and conjugated with methotrexate to form a 5-fluorouracil-methotrexate conjugate (MF). This was complexed with sulfobutyl ether-beta-cyclodextrin (MF-SEBCD) using a stirring method to create an injectable formulation. In vitro studies assessed the conversion of MF-SEBCD in plasma and its antitumor activity. In vivo studies examined antitumor activity, preliminary safety, pharmacokinetics, and tissue distribution. MF was synthesized with a 25% yield and purity above 95%. The water solubility of MF increased by 92-fold with MF-SEBCD preparation. In vitro, MF-SEBCD effectively converted into Fu in plasma and showed strong antitumor activity, with IC50 values of 0.51, 1.29, and 1.26 mu M for MC38, HT29, and 4T1 cells, respectively. In vivo, MF-SEBCD achieved a tumor inhibition rate of 57.08%. Pharmacokinetic studies showed that MF-SEBCD extended Fu's half-life to 47 min, nearly double that of Fu injection. Tissue distribution analysis confirmed improved tumor targeting. MF-SEBCD effectively prolongs Fu's half-life, enhances tumor targeting, increases antitumor efficacy, and reduces side effects, offering a promising approach for colorectal cancer treatment.


  • Open Access

    Natural-source payloads used in the conjugated drugs architecture for cancer therapy: Recent advances and future directions

    by Cuiping Li, Kourong Shi, Siyuan Zhao, Juan Liu, Qiaoli Zhai, Xiaoli Hou, Jie Xu, Xinyu Wang, Jiahui Liu, Xin Wu, et al.